Cell MedX Corp. – ‘10-K’ for 5/31/22 – ‘EX-21.1’

On:  Friday, 4/7/23, at 3:03pm ET   ·   For:  5/31/22   ·   Accession #:  1393905-23-167   ·   File #:  0-54500

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Annual Report   —   Form 10-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Cell Medx Corp. - Form 10-K SEC Filing              HTML    801K 
 2: EX-10.50    Loan Agreement and Note Payable Dated April 28,     HTML     30K 
                2022, Among Cell Medx (Canada) Corp. and Richard                 
                Jeffs                                                            
 3: EX-10.51    Loan Agreement and Note Payable Dated May 31,       HTML     30K 
                2022, Among Cell Medx (Canada) Corp. and Richard                 
                Jeffs                                                            
 4: EX-10.52    Loan Agreement and Note Payable Dated June 27,      HTML     30K 
                2022, Among Cell Medx (Canada) Corp. and Richard                 
                Jeffs                                                            
 5: EX-10.53    Loan Agreement and Note Payable Dated July 28,      HTML     30K 
                2022, Among Cell Medx (Canada) Corp. and Richard                 
                Jeffs                                                            
 6: EX-10.59    Loan Agreement Dated September 2, 2022, Among Cell  HTML     27K 
                Medx (Canada) Corp. and Richard Jeffs                            
 7: EX-10.60    Loan Agreement Dated September 6, 2022, Among Cell  HTML     28K 
                Medx (Canada) Corp. and Richard Jeffs                            
 8: EX-10.61    Loan Agreement Dated November 3, 2022, Among Cell   HTML     28K 
                Medx (Canada) Corp. and Richard Jeffs                            
 9: EX-10.62    Loan Agreement Dated November 28, 2022, Among Cell  HTML     31K 
                Medx (Canada) Corp. and Richard Jeffs                            
10: EX-10.63    Loan Agreement Dated December 30, 2022, Among Cell  HTML     28K 
                Medx (Canada) Corp. and Richard Jeffs                            
11: EX-10.64    Loan Agreement Dated January 24, 2023, Among Cell   HTML     32K 
                Medx Corp. and David Jeffs                                       
12: EX-10.65    Loan Agreement Dated January 24, 2023, Among Cell   HTML     32K 
                Medx Corp. and Amir Vahabzadeh                                   
13: EX-10.66    Loan Agreement Dated January 30, 2022, Among Cell   HTML     27K 
                Medx (Canada) Corp. and Richard Jeffs                            
14: EX-21.1     List of Significant Subsidiaries                    HTML     26K 
15: EX-31.1     Certification -- §302 - SOA'02                      HTML     29K 
16: EX-31.2     Certification -- §302 - SOA'02                      HTML     29K 
17: EX-32.1     Certification -- §906 - SOA'02                      HTML     26K 
18: EX-32.2     Certification -- §906 - SOA'02                      HTML     26K 
24: R1          Document and Entity Information                     HTML     86K 
25: R2          Consolidated Balance Sheets                         HTML    106K 
26: R3          Consolidated Balance Sheets - Parenthetical         HTML     33K 
27: R4          Consolidated Statements of Operations               HTML     99K 
28: R5          Consolidated Statement of Stockholders' Deficit     HTML     86K 
29: R6          Consolidated Statements of Cash Flows               HTML     97K 
30: R7          Organization and Nature of Operations               HTML     31K 
31: R8          Summary of Significant Accounting Policies          HTML     48K 
32: R9          Related Party Transactions Disclosure               HTML     48K 
33: R10         Notes and Advances Payable Disclosure               HTML     47K 
34: R11         Other Current Assets Disclosure                     HTML     28K 
35: R12         Equipment Disclosure                                HTML     34K 
36: R13         Revenue Disclosure                                  HTML     34K 
37: R14         Notes and Advances Payable Disclosure, Current      HTML     28K 
38: R15         Stockholders' Deficit Disclosure                    HTML     59K 
39: R16         Income Taxes Disclosure                             HTML     47K 
40: R17         Subsequent Events Disclosure                        HTML     30K 
41: R18         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis   HTML     28K 
                of Presentation (Policies)                                       
42: R19         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:         HTML     29K 
                Principles of Consolidation, Policy (Policies)                   
43: R20         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:         HTML     31K 
                Accounting Estimates, Policy (Policies)                          
44: R21         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:         HTML     30K 
                Foreign Currency Translations and Transactions,                  
                Policy (Policies)                                                
45: R22         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:         HTML     30K 
                Revenue Recognition, Policy (Policies)                           
46: R23         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:         HTML     30K 
                Inventory Valuation, Policy (Policies)                           
47: R24         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:         HTML     29K 
                Research and Development Costs, Policy (Policies)                
48: R25         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Income  HTML     31K 
                Taxes, Policy (Policies)                                         
49: R26         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:         HTML     34K 
                Earnings Per Share, Policy (Policies)                            
50: R27         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:         HTML     30K 
                Long-lived Assets, Policy (Policies)                             
51: R28         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:         HTML     29K 
                Equipment, Policy (Policies)                                     
52: R29         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair    HTML     31K 
                Value Measurements, Policy (Policies)                            
53: R30         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock   HTML     32K 
                Options and Other Stock-based Compensation, Policy               
                (Policies)                                                       
54: R31         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent  HTML     28K 
                Accounting Pronouncements (Policies)                             
55: R32         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:         HTML     33K 
                Earnings Per Share, Policy: Schedule of                          
                Antidilutive Securities Excluded from Computation                
                of Earnings Per Share (Tables)                                   
56: R33         Related Party Transactions Disclosure: Schedule of  HTML     36K 
                Amounts Due to Related Parties (Tables)                          
57: R34         Related Party Transactions Disclosure: Schedule of  HTML     36K 
                Transactions with Related Parties (Tables)                       
58: R35         Notes and Advances Payable Disclosure: Schedule of  HTML     39K 
                Loans and Advances Outstanding to Related Parties                
                (Tables)                                                         
59: R36         Equipment Disclosure: Change in book value of the   HTML     33K 
                equipment (Tables)                                               
60: R37         Revenue Disclosure: Schedule of Revenue and         HTML     34K 
                Associated Costs (Tables)                                        
61: R38         Stockholders' Deficit Disclosure: Schedule of       HTML     36K 
                Stock Option Activity (Tables)                                   
62: R39         Stockholders' Deficit Disclosure: Schedule of       HTML     31K 
                Stock Options Outstanding (Tables)                               
63: R40         Stockholders' Deficit Disclosure: Schedule of       HTML     36K 
                Warrant Activity (Tables)                                        
64: R41         Stockholders' Deficit Disclosure: Schedule of       HTML     32K 
                Warrant Details (Tables)                                         
65: R42         Income Taxes Disclosure: Schedule of Effective      HTML     37K 
                Income Tax Rate Reconciliation (Tables)                          
66: R43         Income Taxes Disclosure: Schedule of Deferred Tax   HTML     34K 
                Assets and Liabilities (Tables)                                  
67: R44         Organization and Nature of Operations (Details)     HTML     30K 
68: R45         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:         HTML     31K 
                Earnings Per Share, Policy: Schedule of                          
                Antidilutive Securities Excluded from Computation                
                of Earnings Per Share (Details)                                  
69: R46         Related Party Transactions Disclosure: Schedule of  HTML     39K 
                Amounts Due to Related Parties (Details)                         
70: R47         Related Party Transactions Disclosure: Schedule of  HTML     40K 
                Transactions with Related Parties (Details)                      
71: R48         Notes and Advances Payable Disclosure: Schedule of  HTML     39K 
                Loans and Advances Outstanding to Related Parties                
                (Details)                                                        
72: R49         Notes and Advances Payable Disclosure (Details)     HTML     65K 
73: R50         Other Current Assets Disclosure (Details)           HTML     30K 
74: R51         Equipment Disclosure: Change in book value of the   HTML     36K 
                equipment (Details)                                              
75: R52         Revenue Disclosure: Schedule of Revenue and         HTML     49K 
                Associated Costs (Details)                                       
76: R53         Notes and Advances Payable Disclosure, Current      HTML     35K 
                (Details)                                                        
77: R54         Stockholders' Deficit Disclosure (Details)          HTML     78K 
78: R55         Stockholders' Deficit Disclosure: Schedule of       HTML     41K 
                Stock Option Activity (Details)                                  
79: R56         Stockholders' Deficit Disclosure: Schedule of       HTML     31K 
                Stock Options Outstanding (Details)                              
80: R57         Stockholders' Deficit Disclosure: Schedule of       HTML     34K 
                Warrant Activity (Details)                                       
81: R58         Stockholders' Deficit Disclosure: Schedule of       HTML     33K 
                Warrant Details (Details)                                        
82: R59         Income Taxes Disclosure: Schedule of Effective      HTML     54K 
                Income Tax Rate Reconciliation (Details)                         
83: R60         Income Taxes Disclosure: Schedule of Deferred Tax   HTML     37K 
                Assets and Liabilities (Details)                                 
84: R61         Income Taxes Disclosure (Details)                   HTML     30K 
85: R62         Subsequent Events Disclosure (Details)              HTML     34K 
88: XML         IDEA XML File -- Filing Summary                      XML    153K 
86: XML         XBRL Instance -- cmxc-20220531_htm                   XML    666K 
87: EXCEL       IDEA Workbook of Financial Reports                  XLSX     98K 
19: EX-101.CAL  XBRL Calculations -- cmxc-20220531_cal               XML     69K 
20: EX-101.DEF  XBRL Definitions -- cmxc-20220531_def                XML    298K 
21: EX-101.LAB  XBRL Labels -- cmxc-20220531_lab                     XML    526K 
22: EX-101.PRE  XBRL Presentations -- cmxc-20220531_pre              XML    484K 
23: EX-101.SCH  XBRL Schema -- cmxc-20220531                         XSD    145K 
89: JSON        XBRL Instance as JSON Data -- MetaLinks              258±   387K 
90: ZIP         XBRL Zipped Folder -- 0001393905-23-000167-xbrl      Zip    222K 

‘EX-21.1’   —   List of Significant Subsidiaries

This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]

7 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/15/24  Cell MedX Corp.                   10-Q        2/29/24   53:2.7M                                   Empire Stock Transf… Inc
 1/16/24  Cell MedX Corp.                   10-Q       11/30/23   46:2.3M                                   Empire Stock Transf… Inc
10/16/23  Cell MedX Corp.                   10-Q        8/31/23   42:1.9M                                   Empire Stock Transf… Inc
 9/01/23  Cell MedX Corp.                   10-K        5/31/23   73:3.2M                                   Empire Stock Transf… Inc
 6/29/23  Cell MedX Corp.                   10-Q        2/28/23   53:2.5M                                   Empire Stock Transf… Inc
 5/19/23  Cell MedX Corp.                   10-Q       11/30/22   53:2.4M                                   Empire Stock Transf… Inc
 4/19/23  Cell MedX Corp.                   10-Q        8/31/22   51:2.2M                                   Empire Stock Transf… Inc

22 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/18/22  Cell MedX Corp.                   8-K:1,7,8,910/11/22   17:284K                                   Empire Stock Transf… Inc
 4/11/22  Cell MedX Corp.                   10-Q        2/28/22   56:2.5M                                   Empire Stock Transf… Inc
 1/12/22  Cell MedX Corp.                   10-Q       11/30/21   54:2.4M                                   Empire Stock Transf… Inc
 8/30/21  Cell MedX Corp.                   10-K        5/31/21   83:3.7M                                   Empire Stock Transf… Inc
 5/26/21  Cell MedX Corp.                   8-K:1,3,7,9 5/24/21    4:95K                                    Empire Stock Transf… Inc
 4/09/21  Cell MedX Corp.                   10-Q        2/28/21   56:2.8M                                   Empire Stock Transf… Inc
 1/14/21  Cell MedX Corp.                   10-Q       11/30/20   53:2M                                     Empire Stock Transf… Inc
 9/15/20  Cell MedX Corp.                   10-K        5/31/20   84:2.9M                                   Empire Stock Transf… Inc
 4/14/20  Cell MedX Corp.                   10-Q        2/29/20   67:2.2M                                   Empire Stock Transf… Inc
 1/31/20  Cell MedX Corp.                   8-K:1,9     1/29/20    3:69K                                    Empire Stock Transf… Inc
 1/14/20  Cell MedX Corp.                   10-Q       11/30/19   65:2.2M                                   Empire Stock Transf… Inc
12/31/18  Cell MedX Corp.                   8-K:1,3,9  12/27/18    3:248K                                   Empire Stock Transf… Inc
 9/13/18  Cell MedX Corp.                   10-K        5/31/18   85:3M                                     Empire Stock Transf… Inc
10/17/17  Cell MedX Corp.                   10-Q        8/31/17   59:2.2M                                   Empire Stock Transf… Inc
 8/11/15  Cell MedX Corp.                   8-K:5,9     8/11/15    3:172K                                   Ideal Connection, Inc/FA
11/18/14  Cell MedX Corp.                   8-K:1,9    11/13/14    2:48K                                    Ideal Connection, Inc/FA
11/03/14  Cell MedX Corp.                   8-K:1,9    10/28/14    2:60K                                    Ideal Connection, Inc/FA
10/17/14  Cell MedX Corp.                   8-K:1,9    10/16/14    3:407K                                   Ideal Connection, Inc/FA
10/09/14  Cell MedX Corp.                   10-Q        8/31/14   37:2.9M                                   Ideal Connection, Inc/FA
 8/26/14  Cell MedX Corp.                   10-K        5/31/14   37:1.8M                                   Ideal Connection, Inc/FA
10/13/10  Cell MedX Corp.                   S-1/A                  8:1.2M                                   Toppan Merrill/FA
 7/13/10  Cell MedX Corp.                   S-1                   11:921K                                   Toppan Merrill/FA